X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pomalidomide (509) 509
index medicus (320) 320
multiple myeloma (291) 291
lenalidomide (278) 278
humans (248) 248
hematology (186) 186
oncology (173) 173
thalidomide - analogs & derivatives (161) 161
thalidomide (154) 154
bortezomib (148) 148
multiple myeloma - drug therapy (147) 147
dexamethasone (126) 126
male (102) 102
female (101) 101
therapy (96) 96
carfilzomib (93) 93
low-dose dexamethasone (90) 90
aged (81) 81
middle aged (78) 78
thalidomide - therapeutic use (75) 75
survival (71) 71
thalidomide - administration & dosage (69) 69
animals (66) 66
adult (63) 63
pharmacology & pharmacy (63) 63
antineoplastic combined chemotherapy protocols - therapeutic use (62) 62
daratumumab (62) 62
treatment outcome (58) 58
open-label (57) 57
combination (53) 53
multiple myeloma - pathology (52) 52
dexamethasone - administration & dosage (51) 51
immunomodulatory drugs (51) 51
thalidomide - pharmacology (51) 51
patients (49) 49
stem-cell transplantation (49) 49
aged, 80 and over (47) 47
drug therapy (47) 47
immunomodulation (47) 47
care and treatment (43) 43
immunologic factors - therapeutic use (43) 43
multiple-myeloma (43) 43
cereblon (40) 40
lenalidomide plus dexamethasone (40) 40
cancer (39) 39
immunotherapy (36) 36
analysis (35) 35
antineoplastic agents - therapeutic use (35) 35
cells (35) 35
thalidomide - adverse effects (35) 35
efficacy (34) 34
refractory multiple-myeloma (34) 34
recurrence (33) 33
research (32) 32
elotuzumab (31) 31
multiple myeloma - mortality (31) 31
prognosis (31) 31
antineoplastic combined chemotherapy protocols - adverse effects (30) 30
t-cells (30) 30
chemotherapy (29) 29
imids (29) 29
mice (29) 29
myeloma (28) 28
degradation (27) 27
immunology (27) 27
medicine & public health (27) 27
abridged index medicus (26) 26
survival analysis (26) 26
clinical trials (25) 25
immunologic factors - pharmacology (25) 25
ixazomib (25) 25
proteins (25) 25
survival rate (25) 25
transplantation (25) 25
medical prognosis (24) 24
monoclonal antibodies (24) 24
proteasome inhibitors (24) 24
relapse (24) 24
thalidomide analogs (24) 24
cyclophosphamide (23) 23
anemia (22) 22
antineoplastic agents - pharmacology (22) 22
cell line, tumor (22) 22
expression (22) 22
identification (22) 22
pharmacokinetics (22) 22
plus dexamethasone (22) 22
safety (22) 22
target (22) 22
daratumumab monotherapy (21) 21
dosage and administration (21) 21
drug dosages (21) 21
health aspects (21) 21
hematology, oncology and palliative medicine (21) 21
leukemia (21) 21
multiple myeloma - metabolism (21) 21
angiogenesis (20) 20
clinical trials as topic (20) 20
dose-response relationship, drug (20) 20
medicine, research & experimental (20) 20
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (502) 502
Polish (12) 12
French (8) 8
Russian (8) 8
German (7) 7
Japanese (2) 2
Persian (2) 2
Chinese (1) 1
Czech (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Blood, ISSN 0006-4971, 11/2018, Volume 132, Issue Supplement 1, pp. 5648 - 5648
Abstract Background: Pomalidomide is a new generation IMID, with a very good compliance, thanks to oral administration, which can be used also in heavily... 
Journal Article
Blood, ISSN 0006-4971, 12/2015, Volume 126, Issue 23, pp. 1834 - 1834
Abstract Introduction: The introduction of newer agents, such as lenalidomide (LEN) and bortezomib (BORT), has resulted in improved survival outcomes in pts... 
Journal Article
British Journal of Haematology, ISSN 0007-1048, 03/2014, Volume 164, Issue 6, pp. 811 - 821
Summary Cereblon (CRBN), the molecular target of lenalidomide and pomalidomide, is a substrate receptor of the cullin ring E3 ubiquitin ligase complex,... 
lenalidomide | Cereblon | Ikaros | pomalidomide | Aiolos | Pomalidomide | Lenalidomide | Ubiquitin | Genetic transcription | T cells | Ligases | Analysis | Haematological Malignancy
Journal Article
Leukemia, ISSN 0887-6924, 12/2017
During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved treatment... 
Journal Article
Blood, ISSN 0006-4971, 02/2018, Volume 131, Issue 8, pp. 855 - 863
Novel therapies are needed for patients with relapsed or refractory multiple myeloma (MM). We conducted a multicenter, phase 1 study in advanced hematological... 
DARATUMUMAB | SINGLE-AGENT | DEXAMETHASONE | CARFILZOMIB | NUCLEAR EXPORT | OPEN-LABEL | PHASE-2 | XPO1/CRM1 | INHIBITOR | HEMATOLOGY | POMALIDOMIDE
Journal Article
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 2015, Volume 16, Issue 8, pp. 3163 - 3166
Journal Article
Haematologica, ISSN 0390-6078, 10/2015, Volume 100, Issue 10, pp. 1327 - 1333
Journal Article
Journal Article
NATURE, ISSN 0028-0836, 08/2014, Volume 512, Issue 7512, pp. 49 - 49
In the 1950s, the drug thalidomide, administered as a sedative to pregnant women, led to the birth of thousands of children with multiple defects. Despite the... 
MULTIPLE-MYELOMA | CELLS | PROTEIN | MENTAL-RETARDATION | RECOGNITION | MULTIDISCIPLINARY SCIENCES | LENALIDOMIDE | CEREBLON | POMALIDOMIDE | CANCER | CONGENITAL ABNORMALITIES
Journal Article
Journal Article
Oncotarget, ISSN 1949-2553, 10/2018, Volume 9, Issue 84, pp. 35476 - 35477
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 11, pp. 1055 - 1066
Journal Article
Journal Article
Journal Article